Pei Swam Ng
Introduction
T2DM is a common chronic metabolic disease which is increasing all over the world. Currently, there is no
known cure but the disease can only be controlled to improve the quality of life.
Objective
To investigate the potential of Stromal Vascular Fraction (SVF) for glycaemic control in T2DM patients.
Background
55 years old gentleman with underlying T2DM since year 2009 and was started on oral anti-diabetic (OAD)
agents for the past 10 years. In view of his poor glycaemic control despite on optimal conventional
medications, he consented to undergo Allogenic SVF therapy.
Method
Careful preparation measures were taken including proper selection of donor through screening. SVF cells
isolated and prepared in sterile setting. The patient underwent 3 sessions of Allogenic SVF therapy started
in Oct 2018, followed by Mar 2019 and June 2019. Each of the sessions, patient received 30ml SVF derived
from 50ml condensed adipose tissue (approximately 50-100,000 MSC per ml of adipose tissue) by
intravenous injection.
Result
Follow up was carried out 1 month after each session of Allogenic SVF therapy. Fasting glucose reduced
from 12.4mmol/L to 7.6mmol/L and HbA1c reduced from 7.6% to 6.9%. Patient’s OAD agent dosage
adjusted and no complication was observed.
Conclusion
We demonstrated the safety administration of intravenous Allogenic SVF. Despite conventional treatment,
we hope to encourage more SVF research for glycaemic control in T2DM and develop an effective stem-cell
based treatment for diabetes.
